Vancouver, BC - The PET and Recovery Following Revascularization (PARR-2) trial showed that, among patients with severe left ventricular (LV) dysfunction, those who received fluorodeoxyglucose (FDG) ...

Please provide your email address to receive an email when new articles are posted on . Key risk factors that may predict severe disease in patients with MIS-C include fever greater than 103.1 degrees ...

In patients with severe left ventricular systolic dysfunction on optimal medical therapy for HF, undergoing PCI did not improve rates of all-cause death or HF hospitalization, according to the results ...

Patients enrolled in the ISCHEMIA trial with a history of heart failure or left ventricular dysfunction randomized to invasive management with either PCI or CABG surgery had significantly better ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

Percutaneous coronary intervention (PCI) does not reduce all-cause mortality or heart failure hospitalization in patients with severe left ventricular dysfunction and extensive coronary artery disease ...

High levels of inflammatory biomarkers are associated with a higher incidence of acute heart failure (HF), increased risk of readmission, and higher mortality. 1 There is also a strong correlation ...

Patients with embolic stroke of undetermined source (ESUS) who are found to have signs of left ventricular dysfunction may benefit from anticoagulation to prevent a further stroke, a new exploratory ...

Among young adults with aortic regurgitation (AR), those undergoing aortic valve replacement (AVR) before they met standard criteria were more likely to achieve good results from the surgery, a study ...